Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 301–400 of 1,001
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Hahne, J. C., & Valeri, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00226 · Cited by 75
Scartozzi, M., Bearzi, I., Mandolesi, A., Pierantoni, C., Loupakis, F., Zaniboni, A., Negri, F., Quadri, A., Zorzi, F., Galizia, E., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-303 · Cited by 72
Are BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 80
Élez, E., Argilés, G., & Tabernero, J. M. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0369-x · Cited by 83
Abdel-Rahman, O. M., & Fouad, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.07.005 · Cited by 76
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 79
Adam, R. A., Haller, D. G., Poston, G. J., Raoul, J., Spano, J., Tabernero, J. M., & Cutsem, E. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq043 · Cited by 78
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
Di Fiore, F., Sesboüé, R., Michel, P., Sabourin, J. C., & Frebourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 71
The road to resistance: EGFR mutation and cetuximab
Bardelli, A., & Janne, P. A. (2012) · Nature Medicine · doi:10.1038/nm.2646 · Cited by 86
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2029 · Cited by 80
Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 68
Clinical utility of whole-genome sequencing in precision oncology
Rosenquist, R., Cuppen, E. P. J. G., Buettner, R., Caldas, C., Dreau, H. M.-P., Elemento, O., Frederix, G., Grimmond, S. M., Haferlach, T., Jobanputra, V., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.018 · Cited by 79
De, S., Paul, S., Manna, A., Majumder, C., Pal, K., Casarcia, N., Mondal, A., Banerjee, S., Nelson, V. K., Ghosh, S., et al. (2023) · Cancers · doi:10.3390/cancers15030993 · Cited by 76
Modest, D. P., Laubender, R. P., Stintzing, S., Giessen, C. A., Schulz, C. U., Haas, M., Mansmann, U., & Heinemann, V. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.752580 · Cited by 79
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
Eng, C. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.16 · Cited by 81
EGFR inhibition in the treatment of non‐small cell lung cancer
Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 74
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Carethers, J. M. (2008) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08093607 · Cited by 82
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 76
“17, a randomized phase III trial, evaluated the efficacy of cetuximab single agent in mCRC patients’ refractory to fluoropyrimidines, irinotecan, and oxaliplatin [15].”
BackgroundKay, A., Higgins, J., Day, A. G., Meyer, R. M., & Booth, C. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr492 · Cited by 72
Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 75
Suenaga, M., Mizunuma, N., Matsusaka, S., Shinozaki, E., Ozaka, M., Ogura, M., & Yamaguchi, T. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85567 · Cited by 74
Adelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 75
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 80
Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases
Tong, C. C. L., Ko, E. C., Sung, M. W., Cesaretti, J. A., Stock, R. G., Packer, S. H., Forsythe, K., Genden, E. M., Schwartz, M., Lau, K. H. V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036979 · Cited by 74
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
Baas, J. M., Krens, L. L., Guchelaar, H., Ouwerkerk, J., de Jong, F. A., Lavrijsen, A. P. M., & Gelderblom, H. A. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.004 · Cited by 69
Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
Amir, E., Šeruga, B., Martínez‐López, J., Kwong, R. C., Pandiella, A., Tannock, I. F., & Ocaña, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2393 · Cited by 73
Voisin, L., Julien, C., Duhamel, S., Gopalbhai, K., Claveau, I., Saba-El-Leil, M. K., Rodrigue-Gervais, I. G., Gaboury, L., Lamarre, D., Basik, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-337 · Cited by 69
Garrido‐Laguna, I., McGregor, K., Wade, M. L., Weis, J. R., Gilcrease, W., Burr, L., Soldi, R., Jakubowski, L., Davidson, C., Morrell, G., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9947-6 · Cited by 71
Sastre, J., Aranda, E., Grávalos, C., Massutí, B., Varella‐Garcia, M., Rivera, F., Soler, G., Carrato, A., Manzano, J. L., Díaz‐Rubio, E., et al. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.11.005 · Cited by 70
Lee, W. S., Ahn, S., Chung, J., Kim, K. O., Kwon, K. A., Kim, Y., Sym, S.-J., Shin, D., Park, I., Lee, U., et al. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00109 · Cited by 86
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T., Alawi, M., Indenbirken, D., Kriegs, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3574 · Cited by 67
KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies
Soulières, D., Greer, W. L., Magliocco, A. M., Huntsman, D. D., Young, S. S., Tsao, M., & Kamel‐Reid, S. (2010) · Current Oncology · doi:10.3747/co.v17is1.614 · Cited by 72
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 74
Murahashi, M., Hijikata, Y., Yamada, K., Tanaka, Y., Kishimoto, J., Inoue, H., Marumoto, T., Takahashi, A., Okazaki, T., Takeda, K., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.03.015 · Cited by 66
Zhang, W., Chen, L., Ma, K., Zhao, Y., Liu, X., Wang, Y., Liu, M., Liang, S., Zhu, H., & Xu, N. (2016) · Oncotarget · doi:10.18632/oncotarget.12207 · Cited by 70
“The anti-EGFR monoclonal antibodies cetuximab (ErbituxTM, Bristol Myers Squibb and Merck KGaA) and panitumumab (VectibixTM, Amgen) are approved for the treatment of metastatic colorectal cancer (mCRC) [29, 30].”
BackgroundPrice, T., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Guan, X., & Peeters, M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.010 · Cited by 66
Self-citationEngineering tumor vasculature on an injection-molded plastic array 3D culture (IMPACT) platform
Lee, S., Lim, J., Yu, J., Ahn, J., Lee, Y., & Jeon, N. L. (2019) · Lab on a Chip · doi:10.1039/c9lc00148d · Cited by 65
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., & Stites, E. C. (2019) · Science Signaling · doi:10.1126/scisignal.aaw8288 · Cited by 65
“Clinical trials have shown that humanized therapeutic antibodies that target EGFR, like cetuximab and panitumumab, provide a survival benefit to colorectal cancer patients (Jonker et al., 2007; Van Cutsem et al., 2007), and these drugs are now approved and utilized for colorectal cancer patients.”
BackgroundBRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 76
Novel Points of Attack for Targeted Cancer Therapy
Røsland, G. V., & Engelsen, A. S. T. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12313 · Cited by 78
Mechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 73
Blank, P. R., Moch, H., Szucs, T. D., & Schwenkglenks, M. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2267 · Cited by 73
Evidence-based Clinical Management of Acute Malignant Colorectal Obstruction
Shimura, T., & Joh, T. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000475 · Cited by 70
EGFR and colon cancer: a clinical view
de Castro, J., Belda-Iniesta, C., Sáenz, E. C., Agudo, E. H., Batlle, J. F., & Barón, M. G. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0147-3 · Cited by 76
“This question has been recently addressed in the NCIC CO.17 study [ 46 ].”
MethodReidy‐Lagunes, D. L., Vakiani, E., Segal, M. F., Hollywood, E. M., Tang, L. H., Solit, D. B., Pietanza, M. C., Capanu, M., & Saltz, L. B. (2012) · Cancer · doi:10.1002/cncr.27459 · Cited by 64
Mao, C., Yuan, J.-Q., Yang, Z., Fu, X., Wu, X., & Tang, J.-L. (2015) · Medicine · doi:10.1097/md.0000000000000775 · Cited by 67
Jiang, Z., Li, C., Li, F., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056205 · Cited by 68
Peeters, M., Price, T. J., & Laethem, J. V. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0167 · Cited by 71
Self-citationSkin toxicities of targeted therapies
Segaert, S., Chiritescu, G., Lemmens, L., Dumon, K., Cutsem, E. V., & Tejpar, S. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70044-9 · Cited by 64
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A.-C., Leong, S., Diamond, J. R., & Eckhardt, S. G. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 61
Scartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0119 · Cited by 63
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Okada, Y., Kimura, T., Nakagawa, T., Okamoto, K., Fukuya, A., Goji, T., Fujimoto, S., Sogabe, M., Miyamoto, H., Muguruma, N., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0383 · Cited by 62
Takahashi, N., Yamada, Y., Furuta, K., Honma, Y., Iwasa, S., Takashima, A., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.230 · Cited by 66
Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly
Holt, P. R., Kozuch, P. S., & Mewar, S. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.10.010 · Cited by 75
Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
Asghar, U. S., Hawkes, E. A., & Cunningham, D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.040 · Cited by 67
Cenigaonandia‐Campillo, A., Serna‐Blasco, R., Gómez-Ocabo, L., Casado, S. S., Baños‐Herraiz, N., del Puerto‐Nevado, L., Cañas, J. A., Fernández‐Aceñero, M. J., García‐Foncillas, J., & Aguilera, Ó. (2021) · Theranostics · doi:10.7150/thno.51265 · Cited by 69
Molecular markers for colon diagnosis, prognosis and targeted therapy
Herzig, D. O., & Tsikitis, V. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23806 · Cited by 70
Colorectal cancer in review: the role of the EGFR pathway
Saif, M. W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003593962 · Cited by 67
Genetic tests and genomic biomarkers: regulation, qualification and validation.
Novelli, G., Ciccacci, C., Borgiani, P., Papaluca, M., & Abadie, E. (2008) · PubMed Central · Cited by 90
Historical perspective: Two decades of progress in treating metastatic colorectal cancer
Lee, R. M., Cardona, K., & Russell, M. C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25431 · Cited by 65
Hecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 68
Cetuximab in the treatment of patients with colorectal cancer
Garrett, C. R., & Eng, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582464 · Cited by 66
Chung, C. H., Seeley, E. H., Röder, H., Grigorieva, J., Tsypin, M., Roder, J., Burtness, B. A., Argiris, A. E., Forastiere, A. A., Gilbert, J., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0937 · Cited by 61
Colorectal Cancer in Young Adults
Zbuk, K. M., Sidebotham, E. L., Bleyer, A., & LaQuaglia, M. P. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.07.008 · Cited by 66
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 65
Eke, I., Storch, K., Krause, M., & Cordes, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0344 · Cited by 58
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 58
Segelov, E., Thavaneswaran, S., Waring, P. M., Desai, J., Robledo, K. P., Gebski, V. J., Elez, E., Nott, L. M., Karapetis, C. S., Lunke, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6843 · Cited by 59
Self-citationGoss, G. D., Vokes, E. E., Gordon, M. S., Gandhi, L., Papadopoulos, K. P., Rasco, D. W., Fischer, J. S., Chu, K. L., Ames, W., Mittapalli, R. K., et al. (2018) · Cancer · doi:10.1002/cncr.31304 · Cited by 59
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers
Lan, Y., Lin, J., Lin, C., Yang, S., Lin, C., Wang, H., Chen, W., Lin, T., Jiang, J., & Chang, S. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23895 · Cited by 62
Riely, G. J., & Ladanyi, M. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080105 · Cited by 69
Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · PubMed · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 53
IgE immunotherapy: A novel concept with promise for the treatment of cancer
Josephs, D. H., Spicer, J. F., Karagiannis, P., Gould, H. J., & Karagiannis, S. N. (2014) · mAbs · doi:10.4161/mabs.27029 · Cited by 58
Role of cMET in the Development and Progression of Colorectal Cancer
Pérez-Vargas, J. C. S., Biondani, P., Maggi, C., Gariboldi, M., Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., Bartolomeo, M. D., de Braud, F., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918056 · Cited by 64
Daly, C., Castanaro, C., Zhang, W., Zhang, Q., Wei, Y., Ni, M., Young, T. M., Zhang, L., Burova, E., & Thurston, G. (2017) · Oncogene · doi:10.1038/onc.2016.216 · Cited by 58
Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific
Roof, A. K., & Gutierrez‐Hartmann, A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.04.019 · Cited by 57
“We were surprised by this finding because EGF is 11 classically described to activate Ras, and the EGF receptor (EGFR) is a target for 12 treatment in many malignant cancers, including colorectal cancer (Jonker et al., 2007).”
BackgroundLiu, J., Zuo, X., Li, C., Yu, T., Gu, X., Zhou, C., Li, Z., Goetz, M., Kießlich, R., & Li, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.044 · Cited by 60
Hypoxia-regulated gene network in drug resistance and cancer progression
Lin, S.-C., Liao, W.-L., Lee, J., & Tsai, S. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214532755 · Cited by 61
Glimelius, B. L. G., & Cavalli‐Björkman, N. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640828 · Cited by 65
Berghoff, A. S., Bartsch, R., Wöehrer, A., Streubel, B., Birner, P., Kros, J. M., Brastianos, P. K., von Deimling, A., & Preusser, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1350-7 · Cited by 61
Wang, Q.-L., Qi, Y., Zhang, D., Gong, C., Yao, A., Xiao, Y., Yang, J., Zhou, F., & Zhou, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2983-9 · Cited by 64
Meetze, K. A., Vincent, S., Tyler, S. M., Mazsa, E. K., Delpero, A. R., Bottega, S., McIntosh, D., Nicoletti, R., Winston, W. M., Weiler, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2407 · Cited by 58
Orditura, M. (2009) · Oncology Reports · doi:10.3892/or_00000319 · Cited by 60
Deboever, G., Hiltrop, N., Cool, M., & Lambrecht, G. L. Y. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.09.003 · Cited by 59
Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer
Grimminger, P., Danenberg, P. V., Dellas, K., Arnold, D., Rödel, C. M., Machiels, J., Haustermans, K. M., Debucquoy, A., Velenik, V., Sempoux, C. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2273 · Cited by 58
Zhang, L., Castanaro, C., Luan, B., Yang, K., Fan, L., Fairhurst, J. L., Rafique, A., Potocky, T. B., Shan, J., Delfino, F. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1033 · Cited by 58
Lièvre, A., Samalin, E., Mitry, E., Assénat, E., Gestin-Boyer, C., Lepère, C., Bachet, J., Portales, F., Vaillant, J.-N., Ychou, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-347 · Cited by 60
Madej, M. P., Coia, G., Williams, C. C., Caine, J. M., Pearce, L. A., Attwood, R. M., Bartone, N., Dolezal, O., Nisbet, R. M., Nuttall, S. D., et al. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.24407 · Cited by 56
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
Hamauchi, S., Yamazaki, K., Masuishi, T., Kito, Y., Komori, A., Tsushima, T., Narita, Y., Todaka, A., Ishihara, M., Yokota, T., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.005 · Cited by 64
Balint, J. P., Gabitzsch, E. S., Rice, A., Latchman, Y., Xu, Y., Messerschmidt, G. L., Chaudhry, A., Morse, M. A., & Jones, F. R. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1706-4 · Cited by 56
Kumar, S. S., Price, T. J., Mohyieldin, O., Borg, M., Townsend, A. R., & Hardingham, J. E. (2014) · Europe PMC (PubMed Central) · Cited by 68
Self-citationKang, B. W., Kim, T. W., Lee, J., Ryu, M., Chang, H. M., Yu, C. S., Kim, J. C., Kim, J. H., Kang, Y., & Lee, J. S. (2008) · Medical Oncology · doi:10.1007/s12032-008-9077-8 · Cited by 57
Martín-Martorell, P., Roselló, S., Rodríguez-Braun, E., Chirivella, I., Bosch, A., & Cervantes, A. M. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604530 · Cited by 55
Cardó‐Vila, M., Giordano, R. J., Sidman, R. L., Bronk, L. F., Fan, Z., Mendelsohn, J. M., Arap, W., & Pasqualini, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915146107 · Cited by 59
Overview of Radiation Therapy for Treating Rectal Cancer
Kye, B., & Cho, H. (2014) · Annals of Coloproctology · doi:10.3393/ac.2014.30.4.165 · Cited by 69
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Teige, I., Mårtensson, L., & Frendéus, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00481 · Cited by 59
“depletion through FcγR-dependent mechanisms (3) Agonist mAb Preferred MoA is FcγR-engaging antibody variant, where FcγRs promote receptor cross-linking and”
BackgroundBenson, A. B., Arnoletti, J. P., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Dilawari, R. A., Engstrom, P. F., Enzinger, P. C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0104 · Cited by 66
Mohan, N., Luo, X. L., Shen, Y., Olson, Z., Agrawal, A., Endo, Y., Rotstein, D. S., Pelosof, L. C., & Wu, W. J. (2021) · Cancers · doi:10.3390/cancers13051027 · Cited by 58
Heskamp, S., Boerman, O. C., Molkenboer‐Kuenen, J. D. M., Oyen, W. J. G., van der Graaf, W. T. A., & van Laarhoven, H. W. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28046 · Cited by 58
Schwarz, R. E., Berlin, J. D., Lenz, H., Nordlinger, B., Rubbia‐Brandt, L., & Choti, M. A. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00558.x · Cited by 58
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.